Home » Updated EMA Biosimilar Guidance Seeks Side-by-Side Quality Analysis
Updated EMA Biosimilar Guidance Seeks Side-by-Side Quality Analysis
June 7, 2012
Biosimilars’ molecular characteristics should mirror those of the reference biologic as closely as possible, while the performance and consistency of the biosimilars’ manufacturing process should stand on its own, the European Medicines Agency (EMA) says in an updated guideline. Includes the full text of EMA Guideline on Biosimilar Quality Comparisons.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor